Skip to search formSkip to main contentSkip to account menu

AZD9150

Known as: ISIS 481464, STAT3 Antisense Oligonucleotide ISIS 481464 
An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. STAT3 antisense… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 3215: STAT3 antisense oligonucleotide (ASO) reverses immunosuppression and enhances cytotoxic cell function to enhance PDL1 blockade
Danvatirsen (AZD9150) is a therapeutic antisense oligonucleotide that selectively targets human STAT3, a ubiquitously expressed… 
2018
2018
Abstract CT103: Rationale for flat dosing of AZD9150 by population pharmacokinetic analysis
Objective: AZD9150 (ISIS 481464) is a 16-nucleotide oligonucleotide antisense molecule designed to reduce expression of human… 
2017
2017
Abstract 3684: Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models
AZD9150, a gen2.5 antisense oligonucleotide (ASO) targeting human STAT3, has improved drug-like properties compared to previous… 
2016
2016
STAT3 inhibition for cancer therapy: Cell-autonomous effects only?
ABSTRACT A paper recently published in Science Translational Medicine describes a next-generation antisense oligonucleotide that… 
2016
2016
A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid…
2016
2016
Abstract 2439: Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150 increases the chemosensitivity and decreases tumor-initiating potential of neuroblastoma cells
Neuroblastoma (NB) is the most common extra-cranial solid tumor in childhood. The long-term, event-free survival of high-risk NB… 
2015
2015
Abstract CT239: Clinical and preclinical evidence of an immune modulating role for the STAT3-targeting ASO AZD9150 and potential to enhance clinical responses to anti-PDL1 therapy
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA AZD9150 is a therapeutic Generation 2.5… 
2014
2014
Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Genomic technologies have greatly expanded our… 
2013
2013
A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.
8523 Background: ISIS 481464 is a synthetic bicyclic nucleic acid-containing antisense oligonucleotide that is complementary to… 
2013
2013
Abstract LB-317: Potentin vivopharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Next generation sequencing technologies have greatly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)